Phibro Animal Health (FRA:PB8) Long-Term Debt: €614 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PB8 Phibro Animal Health Corp FRA:PB8
76 GF Score
Price €32.60
GF Value €27.40
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Phibro Animal Health Long-Term Debt?

Phibro Animal Health FRA:PB8 76 Long-Term Debt is €614 Mil as of Jun. 2026. GuruFocus rates FRA:PB8 with a GF Score™ of 76/100 and a GF Value™ of €27.40 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Phibro Animal Health's Long-Term Debt for the quarter that ended in Jun. 2026 was €614 Mil.

Phibro Animal Health's quarterly Long-Term Debt increased from Dec. 2025 (€607 Mil) to Mar. 2026 (€616 Mil) but then declined from Mar. 2026 (€616 Mil) to Jun. 2026 (€614 Mil).

Phibro Animal Health's annual Long-Term Debt increased from Jun. 2024 (€426 Mil) to Jun. 2025 (€609 Mil) and increased from Jun. 2025 (€609 Mil) to Jun. 2026 (€614 Mil).

Phibro Animal Health  (FRA:PB8) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Phibro Animal Health Long-Term Debt Related Terms

Phibro Animal Health Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Phibro Animal Health's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phibro Animal Health Long-Term Debt Chart

Phibro Animal Health Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 395.36 417.70 425.75 609.01 614.34

Phibro Animal Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 609.01 617.29 606.85 616.47 614.34
FRA:PB8
76GF Score
Phibro Animal Health Corp FRA:PB8
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €614 Mil mean?
Phibro Animal Health (FRA:PB8) has a Long-Term Debt of €614 Mil as of Jun. 2026.
Is Phibro Animal Health's Long-Term Debt too high?
Phibro Animal Health's current Long-Term Debt is €614 Mil. Overall, Phibro Animal Health has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Phibro Animal Health's Long-Term Debt compare to XERS and HROW?
Phibro Animal Health's Long-Term Debt of €614 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Phibro Animal Health's current Long-Term Debt is €614 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phibro Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Phibro Animal Health (FRA:PB8) is currently considered Modestly Overvalued. The stock's GF Value™ is €27.40, compared to a current price of €32.60 — trading 19% above its estimated fair value. The current Long-Term Debt is €614 Mil. Phibro Animal Health's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Phibro Animal Health (FRA:PB8), the current Long-Term Debt is €614 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Phibro Animal Health (FRA:PB8) Overvalued in 2026?

Based on GuruFocus' analysis, Phibro Animal Health stock appears to be overvalued. The current stock price of €32.60 is trading 19% above its estimated GF Value™ of €27.40. GuruFocus considers Phibro Animal Health to be Modestly Overvalued.

Key valuation signals for FRA:PB8:

  • Long-Term Debt: €614 Mil
  • GF Value™: €27.40 vs. price of €32.60 (19% above fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the FRA:PB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Phibro Animal Health Business Description

Other Exchanges PAHC:USAPB8:Germany
Address 300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
76GF Score

Get the complete analysis for FRA:PB8

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.60
Price
€27.40
GF Value